From Food Technology to Functional Food Development: Focus on benefits of Wholegrain Products for Diabetes

Henryk Zielinski1*, Mariusz Piskula1, Danuta Zielinska2 and Juan Antonio Giménez-Bastida3

1Department of Chemistry and Biodynamics of Food, Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences, Tuwima, Olsztyn, Poland
2Department of Chemistry, University of Warmia and Mazury in Olsztyn, Plac Łodzki 4, 10-727 Olsztyn, Poland
3Department of Pharmacology, Vanderbilt University School of Medicine, RRB 514, 23rd Ave. S. at Pierce, Nashville, TN 37232-6602, USA

Abstract

This review article discusses the link between food technology and functional foods development. A special focus is put on the benefits of whole grain intake in human nutrition for diabetes people. An indication for buckwheat-based products is provided with focus on the antioxidative and inhibitory activity against formation of advanced glycation end products.

Keywords: Food technology; Functional foods; Antioxidative; Nutrition; Inhibitory.

Focus on Hyperglycaemia

Nowadays, diabetes mellitus is a disorder characterized by hyperglycaemia due to an absolute or relative deficiency of insulin and or insulin resistance. It affects 1–2% of the population worldwide. Type 2 diabetes (T2D) is currently one of the major causes of morbidity and mortality in Europe [1]. Hyperglycaemia has an important role in the
pathogenesis of long-term complications and diabetic patients with poor blood glucose control are particularly at risk. Furthermore, complications appear to affect organs where cells do not require insulin for glucose uptake, such as those of the nervous system, heart, kidneys and small blood vessels. As a consequence, these cells have high concentrations of intracellular glucose during hyperglycaemia. The precise role of hyperglycaemia in the pathogenesis of long-term complications is still unclear. However, an attractive hypothesis and one that has received considerable interest is the role of protein glycation and formation of advanced glycation end products (AGEs). Protein glycation in humans is believed to be implicated in the development of chronic degenerative diseases due to the modification of proteins with carbohydrate-and lipid-derived intermediates resulting in changes of the functional properties of proteins, lipids and DNA [2]. In long-lived tissue proteins, these chemical modifications accumulate with age and may contribute to the pathophysiology of aging and long-term complications of diabetes, atherosclerosis, renal failure and Alzheimer disease [3-5]. AGEs formation is increased in hyperglycaemia and under the influence of oxidative stress [6]. Increased glycation and build-up of tissue AGEs have been implicated in diabetic complications because they can alter enzymic activity, decrease ligand binding, modify protein half-life and alter immunogenicity [4]. Glycation-derived free radicals can cause protein fragmentation and oxidation of nucleic acids and lipids. The amino groups of adenine and guanine bases in DNA are also susceptible to glycation and AGEs formation, probably by reactive intracellular sugars [7]. AGEs could also form on phospholipids and induce lipid peroxidation by a direct reaction between glucose and amino groups on phospholipids such as phosphatidylethanolamine and phosphatidylserine residues [8]. Antioxidants can protect against glycation derived free radicals and may have therapeutic potential whereas transport proteins, for example, caeruloplasmin can bind transition metals such as cupric ions, preventing them from participating in autoxide glycation or glyoxidation reactions. However, the efficiency of these natural defences against glycation and AGEs in vivo is unknown. Antioxidants protect against glycation-derived free radicals and may have therapeutic potential. Vitamin E (800 mg per day) has been shown to reduce levels of glycated haemoglobin and accumulation of AGEs in the arterial walls of diabetic patients [9,10].

**Diabetic Complications and Advanced Glycation End Products (AGES)**

Despite the fact that there are many concepts regarding the processes leading to development of diabetic complications, investigations still focus on the role of advanced glycation end products (AGEs) in pathogenesis of late diabetic complications. Diabetic retinopathy is the most common cause of blindness and characterized by increased proliferation of blood vessels, vascular occlusion, angiogenesis, microaneurysms, haemorrhages and infarction affecting the retina of the eye. AGEs have been detected in retinal blood vessel walls and are believed to contribute towards vascular occlusion and increased permeability of retinal endothelial cells causing vascular leakage. Level of advanced glycation end products is correlated with early preclinical changes specific for diabetic nephropathy and retinopathy. Atherosclerosis is the most serious consequence of long-term diabetes and the major cause of death in these patients. It is characterized by deposition of atherosclerotic plaques on the insides of arterial walls, occlusion of blood flow and eventual myocardial infarction. Increased glycation of low-density lipoprotein (LDL) occurs in diabetes. Glycated LDL is not recognised by the LDL receptor but its uptake by macrophages is enhanced [11] and this may account, at least in part, for the hyperlipidaemia and accelerated foam cell formation observed in diabetic patients. Diabetic neuropathy is characterised by a thickening of the basement membrane, expansion of the mesangium, reduced filtration, albuminuria and ultimately renal failure. AGEs have been detected in renal tissues in amounts that correlate with the severity of diabetic nephropathy [8]. Diabetic neuropathy may present clinically as pain or numbness of limbs or as impotence in men. There is increased glycation of myelin in diabetes. The body has mechanisms to protect against glycation and AGEs such as the liver enzyme, ketoglutaraldehyde dehydrogenase capable of inactivating 3-DG and preventing AGE formation [12].

A key aim of therapy in diabetic patients is to reduce hyperglycaemia and one of the important tools to achieve it is modification of the diet. There is growing interest in natural products with combined anti-glycation and antioxidant properties as they may have reduced T2D risk at higher intake. The investigation of AGEs formation inhibitors has received much attention. Indeed, a number of plant derived flavonoids (quercetin, rutin and kaempferol) with antioxidant activity have been reported to inhibit glycation, at least in vitro [8]. Natural inhibitors have been proven relatively safer for human consumption when compared with synthetic compounds [13]. There have been reports on the inhibitory activities of some phenolic compounds [14,15], colon derived polyphenol catabolites [16-19], extracts from microalgae [20], herbs [13,21,22], mung bean [15], aged garlic [23], wheat bran feruloyl oligosaccharides [24], coffee fractions [18], fermented byproducts [25] and buckwheat hull tea infusion [26] against AGEs formation.

**The Benefits of Whole Grain intake in the Prevention of Type 2 Diabetes**

Of interest in this respect is that epidemiological studies have linked products based on the whole grain (WG) intake to the prevention of T2D [27-29] [22,39,46]. Meta-analyses of prospective cohort studies during the last few years indicate substantial reduction in T2D risk at higher intake of products based on the whole grain (WG) [30]. Still, limited data are available from controlled dietary interventions. Intervention studies with WG diets have, however, reported benefits on glucose metabolism as manifested through lowered fasting glucose [31], lowered fasting insulin or lowered acute insulin
and glucose responses [32,33]. Lowered postprandial glycaemia in response to certain WG cereal products, or suppressed insulin responses in the case of rye, might also contribute to metabolic benefits of a WG diet [34-36]. Over the last few years there the postprandial glycaemia and insulinaemia to wheat and rye products were mainly investigated due to the an increasing awareness of their importance on T2D and metabolic disease risk. Indications are also available suggesting improved insulin secretion with diets included with WG rye bread compared with a control diet with refined wheat bread [37]. Furthermore, in a study where the dietary modification was made by altering the characteristics of the bread products only, it was concluded that exchanging high glycemic index (GI) low dietary fibre (DF) bread for low GI high DF bread during 4 weeks beneficially affected insulin economy in young women at risk of developing T2D [38]. Other studies have failed to show any effect on glucose metabolism [39-41]. Little information is available regarding the impact on emerging risk markers such as oxidative and carbonyl stress and low-grade inflammation. According to Katcher et al. [41] a WG diet lowered C-Reactive Protein (CRP) and Mateo Anson et al. [42] showed postprandial anti-inflammatory effects of WG wheat bread in an ex vivo induced inflammation; whereas in the intervention by Andersson et al. [39] and Brownlee et al. [40], inflammatory markers remained unaffected. Although the majority of intervention studies indicate benefits on risk markers of relevance for developing T2D, effects on individual risk markers in various studies are inconsistent. Differences in the metabolic characteristics of the test subjects, may of course have contributed to this. Also, the different studies have included different cereals. Most of the intervention studies have addressed wheat (or rather mixed cereals, in which wheat dominate), but in some studies WG barley, rye or rice products have been included with favorable outcome on metabolic risk markers. Although a range of potential mechanisms have been put forward related to the presence of phytochemicals, antioxidants and trace minerals, essential knowledge concerning the bioavailability of such components in products from different WG cereals is scarce.

Currently, frequent post-meal hyperglycaemic episodes are considered to promote oxidative stress and induce low-grade inflammation thereby contributing to endothelial damage and T2D [43]. This knowledge provides a possible explanation for the increased risk of CVD seen in T2D [44]. Similarly to the epidemiological evidences of a protective role of a higher WG intake, also low GI diets have been associated with lowered risk factors for T2D and CVD, as well as lowered risk of disease [45]. In consequence, low GI characteristics of WG foods are frequently mentioned as a feature contributing to the health value of WG diets. Moreover, studies with rye products have also indicated that rye favours a postprandial glycaemic profile with a low and sustained glucose increment, and that a measure of the course of glycaemia (Glycaemic Profile, GP; calculated as the duration of net increment in blood glucose/peak glucose; min/mM) better predicted the insulin response. In addition, a higher GP is associated with higher satiety in the late postprandial phase, and a lower voluntary food intake at a subsequent meal [35,36].

Up till now, there is some only a scarce evidences on the effect of wheat and barley diets on insulin sensitivity and metabolic variables in patients with T2D (Frid et al., unpublished results). Fifty-eight patients with diabetes type 2, divided into 4 groups, participated in the intervention dietary studies. They received: (1) refined wheat bread (High Gl, low WG); (2) whole meal wheat bread (High GI, high WG); (3) Kernel based WG wheat bread (Low GI, high WG) and (4) kernel based barley bread (Low GI, high WG). The patients were treated with life-style intervention, and did not receive pharmacological treatment. Primary end-point was insulin first-phase response and insulin sensitivity, measured using the Glucagon Insulin Tolerance Test (GITT) [46]. Secondary end-points were HbA1c, fasting plasma glucose, HDL, LDL, TG, ApoA, ApoB, PAI-1 and high sensitivity (hsCRP). All measures were performed at the beginning and end of each diet period. No differences were seen in any of the above parameters over the diets with refined wheat bread, whole meal wheat bread or kernel based wheat bread, suggesting that the increase in wheat fibre and or lowering of GI in the case of the kernel based wheat product was not capable of affecting metabolic control in these patients. In contrast, dietary enclosure of the low GI, WG kernel based barley bread significantly improved insulin sensitivity as measured with the GITT. No significant effects were seen on other risk markers analysed. The absence of effects on GITT in the case of the diet enclosed with the corresponding low GI kernel based wheat bread, may indicate that the specific combination of dietary fibre and RS in the barley kernel bread promote benefits on insulin sensitivity through a mechanism involving colonic fermentation. Evidence for such a mechanism has been reported in semiacute experiments in healthy subjects fed this type of kernel based barley bread, whereas a kernel based wheat bread was devoid of benefits [47].

Results with WG barley kernel products indicate benefits on glucose tolerance mediated through colonic fermentation of indigestible carbohydrates. Whole grain product constituents may be metabolized by the gut microbiota, which need to be considered when evaluating mechanisms for potential effects of WG on metabolic risk markers of T2D. Major colonic substrates are cereal fibre, but also resistant starch (RS). Studies in humans have also linked enhanced SCFA production, and butyrate in particular, to improved insulin sensitivity and glucose homeostasis [47-49]. Additionally, also other grain components such as e.g. phenolics may enter the large bowel, and be subjected to microbial metabolism [50]. Only part of phytochemicals ingested with food is absorbed. Phytochemicals which were not absorbed in the upper part of the gastrointestinal tract and these which underwent detoxification process in liver and were returned to the small intestine with bile reach the large intestine where they are modified by microbiota [50]. Therefore, profile, number of, and activity of microbiota in the gastrointestinal tract has a huge impact on human metabolomic profile which may in part have an impact on the health status of humans. Food ingredients which were undigested and unabsorbed in the upper sections of digestive tract reach the
colon, there are transformed, providing a source of carbon and energy for bacteria, but they may also exhibit stimulatory or inhibitory effect on bacteria. The colonic microbiota shows diverse deglycosylation activities, thus releasing aglycons that are rapidly degraded to produce simpler phenolic [51,52]. Degradation of flavonoid aglycons involves C-ring cleavage and reactions affecting functional groups, such as dehydroxylation, demethylation or decarboxylation [52]. The metabolic activity of the gut microflora on polyphenols is often responsible for the modulation of the biological activity of these dietary compounds and their potential health effects [19]. Some studies have been published regarding the activity of conjugated metabolites of quercetin [53,54]. Metabolites of bacteria influence on other bacteria, stimulating or inhibiting their growth as well as on host intestinal epithelial cells affecting the permeability of the gut and immune system. Food components reaching the colon are one of the main factors directly influencing microbiota of this part of digestive. A well-balanced and varied diet ensures that the dynamic equilibrium of the intestinal microbiota is “resistant” to the long-term disorder. Proper development and functioning of the digestive system and the host organism is provided by a properly shaped and stable microbiota. Further study require the processes occurring in the “healthy” intestine, in which constituents of a diet, including phytochemicals, may undergo changes under the influence of gut microbiota, and then be absorbed into a host organism, where they can possess specific biological functions. The area associated with changes of phytochemicals in large intestine, including buckwheat phytochemical originating from the diet, requires in-depth research. The complexity of interactions between bacteria as well as the host organism and microbiota with taking into account the impact of dietary components, makes the study of dietary components transformation occurring in the gut with the involvement of bacteria, it becomes crucial to the full understanding of the micro system functioning of large intestine. Up till now, the colonic availability of ferulic acid and its specific colonic metabolites derived from whole wheat grain products ingestion remains to be elucidated [55].

**Buckwheat-based products in the prevention of type 2 diabetes**

There are limited publications which have indicated the potential use of buckwheat as a source of natural products with combined anti-glycation and antioxidant properties [56,57]. In Europe and North America, buckwheat (*Fagopyrum esculentum Moench*) is considered as a high nutritional value pseudo-cereal due to its balanced amino acid composition and high contents of vitamin B1 and B2, lysine, flavonoids, phenolic acids, tocopherols, phytosterols, soluble carbohydrates, D-chiro-inositol, fagopyritol, thiamin-binding proteins and flavone C-glucosides [56,58-60]. Compared to most fruits, vegetables and grain crops, buckwheat contains more rutin (quercetin 3–rutinoside), a highly potent flavonol glucoside with antioxidant, anti-inflammmary, anticarcinogenic [61] and antiglycative properties [8,15-17,62]. Oryzantin and homoorientin, a pair of isomeric compounds, and their 4’-deoxy analogues, namely vitexin and isovitexin are the main flavone C-glucosides present in buckwheat grain [63]. Various biological and pharmacological activities have been attributed to these compounds, such as hypotensive, anti-inflammatory, antispasmodic [64], antioxidant/ free radical scavenging [65,66], radioprotective effects [67] and anti-glycation activities [68-70]. Recently, vitexin and isovitexin in the bovine serum albumin (BSA) - glucose system showed strong inhibitory effects on the formation of fluorescent advanced glycation endproducts (AGEs), comparable to that of rutin, one of the most potent natural AGE inhibitors suggesting that their anti-glycation activities may mainly be due to their radical scavenging capacity [15]. D-Chiro-inositol is an inositol isomer that occurs in relatively high levels in buckwheat seeds [71]. Chemically synthesized D-chiro-inositol has lowered elevated plasma glucose in insulin-resistant monkeys, streptozotocin-treated hyperglycaemic rats, and normal rats after administration intravenously or orally [72,73]. Administering doses of 10 and 20 mg of D-chiro-inositol in the form of natural buckwheat concentrate decreased serum glucose concentrations by 12- 19% in streptozotocin-diabetic rats, however, further studies of the effect of D-chiro-inositol on humans are needed [74]. Recently it has been reported that D-chiro-inositol enriched tarty buckwheat bran extract lowered the blood glucose level in mice, confirming the beneficial effect of this compound by improving glucose tolerance and insucln response to glucose metabolism without affecting body weight [75]. Having all these evidences, buckwheat based-products were found to display various biological activities, including increasing number of lactic acid bacteria in rat intestine, lowering effect on serum glucose concentration in diabetic rats, treatment of allergic inflammation, suppressing cholesterol level, inhibiting protease and scavenging free radicals [74,76,77] [57,34,33]. Among buckwheat based products, extremely interesting seems to be buckwheat enriched dark wheat breads as it is based on whole meal wheat flour and buckwheat flour from milled groats. Because the inhibitory activities of wheat bran feruloyl oligosaccharides have been found to inhibit the formation of AGEs, and their inhibition of free radical generation in the glycation process has been considered as the major mechanism of their anti-glycation activities mediation [24]. Moreover, the recent evidences have indicated that the consumption of buckwheat enhanced wheat bread caused a positive increase of serum antioxidant capacity in humans [78]. These finding, supported by quality and antioxidant property of buckwheat enhanced wheat bread provided by Lin [79], makes buckwheat enhanced wheat bread an attractive product for long term dietary interventions in ‘at risk’ subjects and in subjects with T2D. The role of diet in shaping metabolic profile is not fully elucidated. It is clear that diet have both an acute and chronic effect. Understanding the chronic effects of diet is the most relevant in the terms of nutrition research, and in the terms of the interpretation of food metabolomics data, and the effect on the human body. Previous research on food metabolomics showed, that in addition to exogenous compounds discriminating diet rich and poor in the test product or group of products in biological fluids of volunteers, is changed the level of endogenous substances. It was observed an increase level of creatinine, creatine, trimethylamine N-oxide, taurine, and...
1. and 3-methylhistidine in the urine of persons who were on a diet with a higher content of meat, and increase the level of p-hydroxyphenylacetate derivatives in subjects with a diet without meat but a high amount of fruit and vegetables [80]. Similarly, the study of Walsh [81] showed that a diet with low phytochemicals concentration resulted in elevated levels of creatinine and metylhistidyndy in urine of volunteers while the diet with high content of phytochemicals resulted in increased levels of hippuric acid derivatives. Very often compounds resulting from the activities of the colon microbiota are markers of consumption of plant origin products. Lorach [82] study showed that after ingestion of almonds in the urine of volunteers are present metabolic products of gastrointestinal microbiota, derivatives of hydroxyphenylacetic, hydroxyphenylpropionic, and hydroxyphenylvaleric acid. In other studies, after cocoa consumption in the urine of volunteers’ derivatives of dihydrophenylvalerolactone was detected [82]. All of these issue point to the necessity of conducting research related to the food metabolomics including research on the effects of regular consumption of buckwheat products on the human metabolism, the formation of biomarkers intake and plasma antioxidant capacity of consumers.

Conclusion

In conclusion, we suggest that regular consumption of whole grain products with the participation of buckwheat can lead to significant changes in the metabolome of consumers which may be relevant in the context of the prevention of diabetes type 2 as well as its chronic complications.

Acknowledgments

This review was supported by grant No 2014/15/NZ9/04461 from the National Science Centre, Poland.

Conflict of Interest

The authors confirm that there is no conflicts of interest regarding this manuscript.

Compliance with Ethics Requirements

This article does not contain any studies with human or animal subjects.

References

1. No authors. Intensive blood glucose control with sulphonylureas or metformin and its effect on complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS Group). Lancet. 1998; 352(9131): 837–851.
2. Ames JM. Dietary Maillard Reaction Products: Implications for Human Health and Disease. Czech J Food Sci. 2009; 27: 566–569.
3. Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation end products in diabetic uremia and treatment of renal failure. Lancet. 1994; 343(8912): 1519–1522. doi: 10.1016/S0140-6736(94)92935-1
4. Vlassara H, Palace MR. Diabetes and advanced glycation end products. J Intern Med. 2002; 251(2): 87–101. doi: 10.1046/j.1365-2796.2002.00932.x
5. Lapolla A, Traldi P, Fedele D. Importance of measuring products of non-enzymatic glycation of proteins. Clin Biochem, 2005; 38(2): 103–115. doi: 10.1016/j.clinbiochem.2004.09.007
6. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagens by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994; 43(5): 676–683. doi: 10.2337/diab.43.5.676
7. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991; 40(4): 405-412. doi: 10.2337/diab.40.4.405
8. Ahmed N. Advanced glycation endproducts – role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005; 67(1): 3–21. doi: 10.1016/j.diabres.2004.09.004
9. Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? Diabetes Care. 1991; 14(1): 68–72. doi: 10.2337/diacare.14.1.68
10. Diardino I, Edelstein D, Horvichi S, Araki N, Brownlee M. Vitamin E prevents diabetes-induced formation of arterial wall intracellular advanced glycation endproducts. Diabetes, 1995; 44: 73A.
11. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL. Glycosylation of LDL enhances cholesterol ester synthesis in human monocyte-derived macrophages. Diabetes. 1988; 37(5): 550–557. doi: 10.2337/db87-175.5.550
12. Hata F, Igaki N, Nakamichi T, Masuda S, Nishimoto S, Oimomi M, et al. Suppressive effect of a-ketogluutaraldehyde dehydrogenase on the advanced process of the Maillard reaction. Diabetes Res Clin Pract. 1998; 5: 5413-5417.
13. Luncefard N, Gugliucci A. Ilex paraguariensis extracts inhibit AGE formation more efficiently than green tea. Fitoterapia. 2005; 76(3): 419-427. doi: 10.1016/j.fitote.2005.03.021
14. Wu CH, Yen GC. Inhibitory effect of naturally occuring flavonoids on the formation of advanced glycation end products. J Agric Food Chem. 2005; 53(8): 3167-3173. doi: 10.1021/jf048550u
15. Peng X, Zheng Z, Cheng KW, et al. Inhibitory effect of mung bean extract and its constituents in vitro in the formation of advanced glycation endproducts. Food Chem. 2008; 106(2): 475-481. doi: 10.1016/j. foodchem.2007.06.016
16. Cervantes-Laurean D1, Schramm DD, Boissonneault GA. Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites. J Nutr Biochem. 2006; 17(8): 531-540. doi: 10.1016/j.jnutbio.2005.10.002
17. Pashikanti S, de Alba DR, Boissonneault GA, Cervantes-Laurean D. Rutin metabolites: Novel inhibitors of nonoxidative advanced glycation end products. Free Radic Biol Med. 2010; 48(5): 655-663. doi: 10.1016/j.freeradbiomed.2009.11.019
18. Verzelloni E, Pellacani C, Tagliazucchi D, et al. Antiglycative and neuroprotective activity of colon-derived polyphenol catabolites. Mol Nutr Food Res. 2011; 55: S35-S43. doi: 10.1002/mnfr.201000525
19. Serra A, Macia A, Romero MP, Reguant J, Ortega N, Motilva MJ. Metabolic pathways of the colonic metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. Food Chem. 2012; 130(2): 383-393. doi: 10.1016/j.foodchem.2011.07.055
20. Sun Z, Peng X, Liu J, Fan KW, Wang M, Chen F. Inhibitory effects of microalgal extracts on the formation of advanced glycation end products (AGEs). Food Chem. 2010; 120: 261-267. doi: 10.1016/j.foodchem.2009.10.018
21. Tsuji-Naito K, Saeki H, Hamano M. Inhibitory effects of Chrysanthemum species extracts on formation of advanced glycation end products. Food Chem. 2009; 116(4): 854-859. doi: 10.1016/j.foodchem.2009.03.042
22. Zhang LS, Wang X, Dong LL. Antioxidation and anticylgation of polysaccharides from Misgurnus anguillicaudatus. Food Chem. 2011; 124(1): 183-187. doi: 10.1016/j.foodchem.2010.06.006
23. Ahmad MS, Ahmed N. Anticylgation properties of aged garlic extract: possible role in prevention of diabetic complications. J Nutr. 2006; 136: 5796-5799. doi: 10.1093/jn/136.3.7965
24. Wang J, Sun B, Cao Y, Tian Y. Protein glycation inhibitory activity of wheat bran feruloyl oligosaccharides. Food Chem. 2009; 112(5): 350-353. doi: 10.1016/j.foodchem.2008.05.072
61. Oomah DB, Mazza G. Flavonoids and antioxidative activities in buckwheat. J Agric Food Chem. 1996; 44(7): 1746-1750. doi: 10.1021/jf9508357

62. Duenas M, Surco-Laos F, Gonzalez-Manzano S, Gonzalez-Paramas AM, Santos-Buelga C. Antioxidant properties of major metabolites of quercetin. Eur Food Res Technol. 2011; 232(1): 103-111. doi: 10.1007/s00217-010-1363-y.

63. Zielińska D, Szwara-Nowak D, Zieliński H. Comparison of spectrophotometric and electrochemical methods for the evaluation of antioxidant capacity of buckwheat products after hydrothermal treatment. J Agric Food Photomet. 2007; 55(15): 6124-6131. doi: 10.1021/jf070146f

64. Prabhakar MC, Bamo H, Kumar I, Shamsi MA, Khan SY. Pharmacological investigations on vinitin. Planta Med. 1981; 43(4): 396-403.

65. Bramami L, Aquilano F, Pietta P. Unfermented rooibos tea: quantitative characterization of flavonoids by HPLC-UV and determination of the total antioxidant activity. J Agric Food Chem. 2003; 51(25): 7472-7474. doi: 10.1021/jf0347721

66. Picerno P, Mencherini T, Lauro MR, Barbato F, Aquino R. Phenolic constituents and antioxidant properties of Aflexosoma violaceum leaves. J Agric Food Chem. 2003; 51(22): 6423-6428. doi: 10.1021/jf030284h

67. Hien TV, Hung NB, Hung PM, Duc NB. Radioprotective effects of vitexin for breast cancer patients undergoing radiotherapy with cobalt-60. Integr Cancer Ther. 2002; 1(1): 38-34. doi: 10.1177/153473540200100103

68. Yamaguchi F, Ariga T, Yoshimura Y, Nakazawa H. Antioxidative and anti-glycation activity of garcinol from Garica indica fruit rind. J Agric Food Chem. 2000; 48(2): 180-185. doi: 10.1021/jf990845y

69. Gugliucci A Menini T. The botanical extracts of Ilex paraguariensis prevent methylglyoxal-induced inhibition of plasmogen and antithrombin III. Life Sci. 2002; 72(3): 279-292. doi: 10.1016/s0024-3205(02)02242-7

70. Lee GY, Jang DS, Lee YM, Kim JM, Kim JS. Naphthopyrone glucosides from fruit rind of Cassia tora with inhibitory activity on advanced glycation end products (AGEs) formation. Arch Pharm Res. 2006; 29(7): 587-590. doi: 10.1007/BF02969270

71. Hien TV, Huong NB, Hung PM, Duc NB. Radioprotective effects of vitexin for breast cancer patients undergoing radiotherapy with cobalt-60. Integr Cancer Ther. 2002; 1(1): 38-34. doi: 10.1177/153473540200100103

72. Ortmeyer HK, Larner J, Hansen BC. Effects of D-chiroinositol added to a meal on plasma glucose and insulin in hyperinsulimic rhesus monkeys. Obes Res. 1995; 3: 605-6085. doi: 10.1021/jf9302153

73. Ortmeyer HK, Larner J, Hansen BC. Effects of D-chiroinositol added to a meal on plasma glucose and insulin in hyperinsulimic rhesus monkeys. Obes Res. 1995; 3: 605-6085. doi: 10.1021/jf9302153

74. Kawa JM, Taylor CG, Przybylski R. Buckwheat concentrate reduces serum glucose in streptozotocin-diabetic rats. J Agric Food Chem. 2003; 51(25): 7287-7291. doi: 10.1021/jf0302153

75. Yao Y, Shan F, Jian C, Chen F, Wang M, Ren G. D-chiro-inositol-enriched tartary buckwheat bran extracts lowers the blood glucose level in KK-Ay mice. J Agric Food Chem. 2008; 56(21): 10027-10031. doi: 10.1021/jf080187m

76. Prestamo G, Pedrazuela A, Penas E, Lasuncan MA, Arroyo G. Role of buckwheat diet on rats as prebiotic and healthy food. Nutr Res. 2003; 23(6): 803-814. doi: 10.1016/S0271-5317(03)00074-5

77. Kim SL, Kim SK, Park CH. Introduction and nutritional evaluation of buckweat sprouts as a new vegetable. Food Res Int. 2004; 37: 319-327. doi: 10.1016/j.foodres.2003.12.008

78. Bojianska T, Frančaková H, Chlebo P, Vollmannová A. Rutin content in buckwheat enriched bread and influence of its consumption on plasma total antioxidant status. Czech J Food Sci. 2009; 27: 236-240.

79. Lin LY, Liu HM, Lin SD, Mau JL. Quality and antioxidant property of buckwheat enriched wheat bread. Food Chem. 2009; 112(4): 987-991. doi: 10.1016/j.foodchem.2008.07.022

80. Stella C, Beckwith-Hall B, Cloarec O, et al. Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res. 2006; 5(10): 2780-2788. doi: 10.1021/pr060265y

81. Walsh MC, Brennan L, Pujos-Guillot E, et al. Influence of acute phytochemical intake on human urinary metabolomic profiles. Am J Clin Nutr. 2007; 86(6): 1687-1693. doi: 10.1093/ajcn/86.5.1687

82. Llorach R, Garrido I, Monagas M, et al. Metabolomics study of human urinary metabolite profiles after intake of almond (Prunus dulcis (Mill) D.A. Webb) skin polyphenols. J Proteome Res. 2010; 9(11): 5859-5867. doi: 10.1021/pr100639v